A previous report regarding ALK rearrangement in NSCLC indicated that FISH provides higher sensitivity and specificity than IHC regarding the effects of targeted therapy, and that the interpretation of FISH results is more objective than that of IHC results.17 However, that study included a much smaller number of squamous cell carcinoma cases than adenocarcinoma cases (303 vs. 25 596). The gene discussed is ALK; the disease is squamous cell carcinoma.